Maria E. Suarez-Almazor

2 months ago | thelancet.com | Juan Ruiz |Sharon H. Giordano |Heather Lin |Maria E. Suarez-Almazor

Get full text accessLog in, subscribe or purchase for full access. References1. Balkwill, FTumour necrosis factor and cancerNat Rev Cancer. 2009; 9:361-3712. Chen, AY ∙ Wolchok, JD ∙ Bass, ARTNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol. 2021; 17:213-2233. Annese, V ∙ Beaugerie, L ∙ Egan, L ∙ et al. European evidence-based consensus: inflammatory bowel disease and malignanciesJ Crohns Colitis. 2015; 9:945-9654. Gordon, H ∙ Biancone, L ∙ Fiorino, G ∙ et al.

Jan 7, 2025 | digitalcommons.library.tmc.edu | Sebastian Bruera |Maria E. Suarez-Almazor

Keywordscheckpoint inhibitor therapy, glucocorticoids, immunosuppressants, cancer, immunotherapyAbstractThe emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs).

Feb 14, 2024 | healio.com | Justin Cooper |Shenaz Bagha |Maria E. Suarez-Almazor

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Since 2008, there has been no “consistent increase” in the use of biologic DMARDs in patients with rheumatoid arthritis diagnosed with breast cancer. A lack of clear guidelines may be the reason.

Feb 14, 2024 | brnw.ch | Justin Cooper |Shenaz Bagha |Maria E. Suarez-Almazor

You've successfully added Rheumatology: Rheumatoid Arthritis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Since 2008, there has been no “consistent increase” in the use of biologic DMARDs in patients with rheumatoid arthritis diagnosed with breast cancer.

May 18, 2023 | onlinelibrary.wiley.com | Namrata Singh |Petros Grivas |Una E. Makris |Maria E. Suarez-Almazor

This work is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award K23-AR-079588 to Dr. Singh. Newer disease-modifying antirheumatic drugs (DMARDs) hold promise for improving quality of life and reducing disability related to rheumatoid arthritis (RA) (1).